Mankind Pharma, one of India’s leading pharmaceutical companies, witnessed a remarkable surge in its stock prices, soaring by 9.24% to Rs 1900.15 compared to the previous day’s closing of Rs 1739.20 on the Bombay Stock Exchange (BSE). This surge comes on the heels of the company’s impressive financial performance in the first quarter of the fiscal year 2023-24.
The stock’s performance over the past month has been equally impressive, gaining a significant 9.22%, which is a testament to the market’s confidence in the company’s growth trajectory. The market capitalization of Mankind Pharma stood at an impressive Rs 73,057 crore on the BSE.
Mankind Pharma’s stellar performance in the first quarter of the fiscal year 2023-24 has propelled its stock to new heights. The company reported a robust 66% year-on-year (YoY) rise in net profit for the quarter ending June 2023. The net profit climbed from Rs 298 crore in the corresponding quarter of the previous year to an impressive Rs 494 crore in Q1FY24.
The company’s revenue also witnessed substantial growth, rising by 18% YoY to reach Rs 2579 crore in the same quarter. This increase in revenue underscores Mankind Pharma’s effective strategies in a competitive market, driving both sales and profitability.
Analysts and investors are closely observing the technical indicators and financial metrics that contribute to Mankind Pharma’s upward trajectory. The relative strength index (RSI) of the Mankind Pharma stock currently stands at 46.2, indicating that the stock is trading within a balanced range, neither in the oversold nor overbought zone. This suggests a stable and sustainable growth pattern.
The company’s earnings before interest, tax, depreciation, and amortization (EBITDA) also witnessed an impressive growth of 43% YoY, reaching Rs 660 crore in Q1FY24. Furthermore, the EBITDA margins expanded significantly by 450 basis points YoY to 25.60%, indicating efficient cost management and improved operational efficiency.
Mankind Pharma’s remarkable growth in the domestic market is worth noting. The company achieved a robust 14% YoY growth in the June quarter, outperforming the industry by a notable 1.5 times. This growth was driven by a 12.5% rise in secondary sales and a volume growth of 4.3%, compared to the industry’s growth of 1.4%. Such figures highlight the company’s ability to capitalize on market trends and consumer demands.
The company’s exports business also witnessed an exceptional growth of 214% YoY in Q1FY24, largely due to one-off opportunities in the US market. This diversification of revenue sources bodes well for Mankind Pharma’s overall stability and growth prospects.
Rajeev Juneja, Vice Chairman & Managing Director of Mankind Pharma, expressed his satisfaction with the company’s performance, stating, “We have started the year on a healthy note, with strong double-digit growth in sales and profitability. The pharma segment outperformed the IPM by 1.5X led by volume-led growth and the highest ever chronic share. Our consumer healthcare segment maintained dominant brand leadership in respective categories. We have also seen positive results of our prior initiatives to improve profitability, with EBITDA growing 43% YoY.”
Investors’ positive response to Mankind Pharma’s financial performance is underscored by the company’s IPO performance earlier this year. The IPO, which was listed at a premium of 20.37% against the issue price of Rs 1,080, saw substantial interest from qualified institutional investors, leading to a subscription rate of 15.32 times.
Mankind Pharma’s exceptional Q1 earnings and strategic growth have undoubtedly captured the market’s attention, positioning the company as a promising player in the pharmaceutical sector. With a strong focus on innovation, operational efficiency, and market diversification, the company seems poised for continued success in the quarters ahead.
